Tacalyx GmbH is a Germany-based biotechnology startup founded in 2019. The company is dedicated to developing innovative anti-cancer therapeutics to address the limited treatment options for metastatic malignant tumors. Tacalyx focuses on targeting cancer-specific carbohydrate antigens, known as Tumor Associated Carbohydrate Antigens (TACAs), found on the surfaces of cancer cells. These abnormal glycans are highly specific to cancer and play a significant role in tumor progression and virulence. With a recent €7.00M Seed Round investment from Thuja Capital in 11 June 2024, Tacalyx is poised to advance its promising research and development efforts in high-need cancer indications. Their compelling approach to addressing crucial unmet medical needs positions the company as an exciting prospect in the biotechnology, health care, health and wellness, and life sciences industries.
Tacalyx GmbH
Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need
Berlin, Germany
17 employees
Seed
Total: $14.00M
Biotechnology, Health Care +2
General Information
Berlin, Germany
BounceWatch is an independent company data service, not affiliated with Tacalyx GmbH. To contact Tacalyx GmbH, visit tacalyx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Tacalyx GmbH compare?
A PDF of Tacalyx GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Tacalyx GmbH soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Germany Market
Biotechnology
About Tacalyx GmbH
Business keywords: Cancer therapeutics, Tumor-associated carbohydrate antigens, Metastatic tumors, Glycocalyx, Cancer-specific antigens, TACAs, Max-Planck-Institute of Colloids and Interfaces, Aberrant glycosylation, Carbohydrate synthesis, Antibody development, Immunotherapy, Cancer research, Medical innovation
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | €7.00M | 1 |
|
11 Jun 2024 |
| Seed Round | €7.00M | 6 |
|
25 Sep 2019 |
Tacalyx GmbH Alternatives & Competitors
View All Alternatives
Charting a course to therapeutics for difficult-to-treat cancer.
Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...
Bringing innovative therapies to patients
FAQ About Tacalyx GmbH
Source: BounceWatch company record for Tacalyx GmbH, https://bouncewatch.com/company/tacalyx, updated 25 September 2026. When citing, please name BounceWatch and link this page.
